4-1BB – and CD28 – co-stimulated CAR-T cells also differ in terms of their safety profile, since the occurrence of CRS and ICANS has been reported more frequently in clinical studies evaluating CD28-based products (104, 112–122) (Table 1). This evidence concerns the gene CD28 and congenital rubella syndrome.